Evidence map›Paper›PMID 41048681›Full record

ArticleAdvanced therapeutics2025

Inhalational Delivery of

Hilliard L Kutscher, Maria Tamblin, Shanta Karki, Lee Chaves, Marissa Baird, Afrin Parvin, Evon Smith, Admire Dube, Zhaoqi Zhang, Saptarshi Chakraborty and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hilliard L KutscherInstitute for Lasers, Photonics and Biophotonics, The State University of New York at Buffalo, Buffalo, NY 14260, USA.
Maria TamblinDivision of Allergy, Immunology and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Shanta KarkiDivision of Allergy, Immunology and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Lee ChavesDivision of Allergy, Immunology and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Marissa BairdDivision of Allergy, Immunology and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Afrin ParvinDivision of Allergy, Immunology and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Evon SmithDivision of Allergy, Immunology and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Admire DubePharmaceutics at the School of Pharmacy, University of the Western Cape (UWC), Robert Sobukwe Road, Bellville 7535, South Africa.
Zhaoqi ZhangDepartment of Biostatistics, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Saptarshi ChakrabortyDepartment of Biostatistics, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Patrick KenneyAdult and Pediatric Infectious Disease, The State University of New York at Buffalo, Buffalo, NY 14203, USA.
Jessica L ReynoldsDivision of Allergy, Immunology and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY 14203, USA.

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Institutional Career DevelopmentKL2TR001413 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DUBOCOVICH, MARGARITA L · 2015 to 2024
$4.2M
Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeuticnanoparticles for TBR01AI129649 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI REYNOLDS, JESSICA L · 2018 to 2022
$2.2M
Immunotherapeutic nanoparticles: Implications for the treatment of tuberculosis and HIVR21AI179228 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI REYNOLDS, JESSICA L · 2023 to 2024
$442k
NCATS NIH HHS KL2 TR001413NCATS NIH HHS UL1 TR001412NIAID NIH HHS R01 AI129649NIAID NIH HHS R21 AI179228
6 · The paper itself

Abstract

Despite multiple treatments for tuberculosis (TB), there are ≈10 million new cases and 1.5 million deaths annually, warranting the need for new therapeutics. Major clinical treatment issues include the length of treatment which is associated with patient non-compliance; and poor cellular drug penetration leading to the generation of drug-resistant strains. This study underscores the potential of

Indexed as

alveolar macrophagebeta-glucannanoparticlesrifampintuberculosis

Identifiers

PMID41048681
PMCPMC12492999

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.